TY - JOUR
T1 - Incidence, severity and outcome of central line related complications in pediatric oncology patients; A single center study
AU - van den Bosch, Ceder H.
AU - van der Bruggen, J. Tjomme
AU - Frakking, Florine N.J.
AU - Terwisscha van Scheltinga, Cecilia E.J.
AU - van de Ven, Cornelis P.
AU - van Grotel, Martine
AU - Wellens, Lianne M.
AU - Loeffen, Yvette G.T.
AU - Fiocco, Marta
AU - Wijnen, Marc H.W.A.
N1 - Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.
PY - 2019/9
Y1 - 2019/9
N2 - Background: Central venous access device (CVAD)-related complications are associated with high morbidity rates. This study was performed to underline the importance of CVAD-complication prevention and treatment. Methods: An audit of practice of CVAD-related complications in pediatric oncology patients receiving a CVAD between January 2015 and June 2017 was performed. CVADs included were totally implantable venous access ports (TIVAPs), Hickman–Broviac® (HB), nontunneled, and peripherally inserted CVADs. Results: A total of 201 children, with 307 CVADs, were analyzed. The incidence rates per 1000 CVAD-days for the most common complications were 1.66 for malfunctions, and 1.51 for central line-associated bloodstream infections (CLABSIs). Of all CVADs inserted, 37.1% were removed owing to complications, of which 45.6% were owing to CLABSIs. In 42% of the CLABSIs, the CLABSI could be successfully cured with systemic antibiotic treatment only. Of all included patients, 5.0% were admitted to the intensive care unit owing to CLABSI. The HB-CVAD compared to the TIVAP was a risk factor for CVAD-related complications, CLABSIs and dislocations in particular. Conclusions: The incidence of CVAD-related complications is high. Research on the prevention and treatment of CVAD-related complications in pediatric oncology patients should be a high priority for all health care professionals. Type of study: Prognosis study (retrospective). Level of evidence: Level II.
AB - Background: Central venous access device (CVAD)-related complications are associated with high morbidity rates. This study was performed to underline the importance of CVAD-complication prevention and treatment. Methods: An audit of practice of CVAD-related complications in pediatric oncology patients receiving a CVAD between January 2015 and June 2017 was performed. CVADs included were totally implantable venous access ports (TIVAPs), Hickman–Broviac® (HB), nontunneled, and peripherally inserted CVADs. Results: A total of 201 children, with 307 CVADs, were analyzed. The incidence rates per 1000 CVAD-days for the most common complications were 1.66 for malfunctions, and 1.51 for central line-associated bloodstream infections (CLABSIs). Of all CVADs inserted, 37.1% were removed owing to complications, of which 45.6% were owing to CLABSIs. In 42% of the CLABSIs, the CLABSI could be successfully cured with systemic antibiotic treatment only. Of all included patients, 5.0% were admitted to the intensive care unit owing to CLABSI. The HB-CVAD compared to the TIVAP was a risk factor for CVAD-related complications, CLABSIs and dislocations in particular. Conclusions: The incidence of CVAD-related complications is high. Research on the prevention and treatment of CVAD-related complications in pediatric oncology patients should be a high priority for all health care professionals. Type of study: Prognosis study (retrospective). Level of evidence: Level II.
KW - Central line complications
KW - CLABSI
KW - Pediatric oncology
UR - http://www.scopus.com/inward/record.url?scp=85056164620&partnerID=8YFLogxK
U2 - 10.1016/j.jpedsurg.2018.10.054
DO - 10.1016/j.jpedsurg.2018.10.054
M3 - Article
C2 - 30415957
AN - SCOPUS:85056164620
SN - 0022-3468
VL - 54
SP - 1894
EP - 1900
JO - Journal of Pediatric Surgery
JF - Journal of Pediatric Surgery
IS - 9
ER -